Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AYTU
AYTU logo

AYTU Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Aytu Biopharma Inc (AYTU) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.250
1 Day change
2.74%
52 Week Range
3.060
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

AYTU is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading essentially flat near $2.17, but the technical picture is still weak with bearish moving averages and no strong buy signal from Intellectia. With no recent news, no clear financial update, neutral insider/hedge fund activity, and no supportive catalyst, the setup does not justify an immediate long-term purchase. If the investor is impatient and wants to act now, the best direct choice is to hold off rather than buy.

Technical Analysis

Current price is 2.1706, just above the previous close of 2.16. Momentum is mixed: MACD histogram is slightly positive but contracting, which suggests the short-term move is losing strength. RSI_6 at 43.69 is neutral and does not indicate oversold conditions. The moving average structure is bearish because SMA_200 > SMA_20 > SMA_5, showing the broader trend is still weak. Price is sitting near pivot 2.207, with support at 2.123 and 2.071 and resistance at 2.29 and 2.342. Overall, the chart does not show a convincing bullish breakout or a strong entry trend.

Positive Catalysts

  • No news in the recent week. Intellectia signals do not show a buy setup, and the stock trend model suggests a modest positive month-ahead probability of 12.93%, which is the only mild constructive point. Post-market change was slightly positive at 0.49%, but this is not enough to count as a meaningful catalyst.

Neutral/Negative Catalysts

  • No signal on given stock today for AI Stock Picker and no recent SwingMax signal. Hedge funds are neutral and insiders are neutral, showing no strong accumulation. There is no recent news, no recent congress trading data, and no valuation data to support a re-rating. The bearish moving average structure remains the clearest negative technical factor.

Financial Performance

Latest quarterly financial data was not available because the financial snapshot returned an error, so there is no usable recent-quarter season to evaluate. As a result, there is no evidence here of accelerating revenue or earnings growth that would strengthen the buy case.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible Wall Street upgrade/downgrade trend to support a buy thesis. Based on the available information, Wall Street appears neutral to cautious rather than bullish.

Wall Street analysts forecast AYTU stock price to rise
3 Analyst Rating
Wall Street analysts forecast AYTU stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.190
sliders
Low
7
Averages
9.33
High
13
Current: 2.190
sliders
Low
7
Averages
9.33
High
13
Maxim
Buy
maintain
$9 -> $7
AI Analysis
2025-09-25
Reason
Maxim
Price Target
$9 -> $7
AI Analysis
2025-09-25
maintain
Buy
Reason
Maxim lowered the firm's price target on Aytu BioPharma to $7 from $9 and keeps a Buy rating on the shares. The firm cites the company's Q4 and adjusted EBITDA miss, and while the quarter was the 9th straight quarter of positive adjusted EBITDA, its base business - ADHD+pediatrics - has effectively peaked, the analyst tells investors in a research note. Maxim adds however that in June, Aytu announced it signed an exclusive commercialization agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA, and the firm believes that EXXUA is a transformational asset that can accelerate growth beyond the current ADHD franchise.
Maxim
Buy
downgrade
$9 -> $7
2025-09-24
Reason
Maxim
Price Target
$9 -> $7
2025-09-24
downgrade
Buy
Reason
Maxim lowered the firm's price target on Aytu BioPharma to $7 from $9 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AYTU
Unlock Now

People Also Watch